Ian Chau

List of Publications by Citations

441 papers	24,401 citations	58 h-index	151 g-index
516 ext. papers	29,788 ext. citations	5.6 avg, IF	6.51 L-index

#	Paper	IF	Citations
441	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *New England Journal of Medicine*, **2004**, 351, 337-45	59.2	4112
440	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2018**, 36, 1714-1768	2.2	1740
439	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet, The*, **2014**, 383, 31-39	40	1475
438	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *New England Journal of Medicine*, **2015**, 373, 726-36	59.2	1172
437	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncology, The*, **2016**, 17, 883-895	21.7	783
436	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science*, **2018**, 359, 920-926	33.3	712
435	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet, The*, **2018**, 392, 123-133	40	624
434	Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 5513-8	2.2	606
433	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 859-70	21.7	542
432	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 481-9	21.7	533
431	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. *Lancet Oncology, The*, **2016**, 17, 801-810	21.7	494
430	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncology, The*, **2014**, 15, 78-86	21.7	413
429	Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. *Journal of Clinical Oncology*, **2004**, 22, 2395-403	2.2	393
428	Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. *Journal of Clinical Oncology*, **2006**, 24, 668-74	2.2	361
427	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2018**, 29, iv238-iv255	10.3	355
426	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. *Journal of Clinical Oncology*, **2018**, 36, 2836-2844	2.2	296
425	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *Journal of Clinical Oncology*, **2012**, 30, 1620-7	2.2	293

424	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. *Lancet Oncology, The*, **2013**, 14, 749-59	21.7	284
423	Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. *Lancet Oncology, The*, **2010**, 11, 241-8	21.7	262
422	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncology, The*, **2017**, 18, 1159-1171	21.7	193
421	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. *JAMA Oncology*, **2018**, 4, 384-388	13.4	191
420	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. *Annals of Oncology*, **2015** , 26, 702-708	10.3	190
419	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. *Cancer Discovery*, **2016**, 6, 838-851	24.4	176
418	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. *Annals of Oncology*, **2011**, 22, 2042-2048	10.3	167
417	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. *Journal of Thoracic Oncology*, **2019**, 14, 237-244	8.9	163
416	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. *Annals of Oncology*, **2005**, 16, 549-57	10.3	146
415	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. *Journal of Clinical Oncology* , **2018**, 36, 3477-3484	2.2	139
414	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. *British Journal of Cancer*, **2009**, 101, 1033-8	8.7	138
413	The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. *Journal of Clinical Oncology*, **2004**, 22, 1420-9	2.2	132
412	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. *Cancer Discovery*, **2018**, 8, 1270-1285	24.4	130
411	Guidance on the management of diarrhoea during cancer chemotherapy. *Lancet Oncology, The*, **2014**, 15, e447-60	21.7	128
410	Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. *European Radiology*, **2008**, 18, 903-10	8	128
409	Targeting the human EGFR family in esophagogastric cancer. *Nature Reviews Clinical Oncology*, **2011**, 8, 492-503	19.4	120
408	Adjuvant therapy in colon cancer--what, when and how?. *Annals of Oncology*, **2006**, 17, 1347-59	10.3	117
407	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. *Journal of the National Cancer Institute*, **2019**, 111, 782-794	9.7	113

406	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. *Lancet Oncology, The*, **2019**, 20, 1109-1123	21.7	113
405	Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. *Recent Patents on Anti-Cancer Drug Discovery*, **2009**, 4, 54-72	2.6	111
404	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 420-435	21.7	110
403	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. *Journal of Clinical Oncology*, **2010**, 28, 3945-50	2.2	105
402	Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 456-61	4	105
401	Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. *Journal of Clinical Oncology*, **2002**, 20, 3130-6	2.2	104
400	Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. *British Journal of Cancer*, **2014**, 110, 19-25	8.7	101
399	Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. *Trials*, **2016**, 17, 17	2.8	99
398	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. *Cancer Cell*, **2019**, 36, 35-50.e9	24.3	94
397	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). *Oncologist*, **2018**, 23, 1407-e136	5.7	91
396	Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. *Haematologica*, **2007**, 92, 271-2	6.6	86
395	Treatment in advanced colorectal cancer: what, when and how?. *British Journal of Cancer*, **2009**, 100, 1704-19	8.7	81
394	Does surgery have a role in managing incurable gastric cancer?. *Nature Reviews Clinical Oncology*, **2015**, 12, 676-82	19.4	75
393	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. *Journal of Clinical Oncology*, **2017**, 35, 2279-2287	2.2	74
392	Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. *British Journal of Cancer*, **2003**, 88, 1017-24	8.7	68
391	Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. *Annals of Oncology*, **2015**, 26, 804-811	10.3	67
390	EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. *Annals of Oncology*, **2014**, 25, 858-863	10.3	64
389	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. *British Journal of Cancer*, **2017**, 117, 1478-1485	8.7	64

388	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. *Annals of Oncology*, **2017**, 28, 2932-2942	10.3	63
387	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. *British Journal of Cancer*, **2006**, 94, 1107-15	8.7	63
386	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. *British Journal of Cancer*, **2003**, 88, 1859-65	8.7	63
385	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. *JAMA Oncology*, **2017**, 3, 235-243	13.4	59
384	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. *British Journal of Cancer*, **2004**, 91, 1453-8	8.7	58
383	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. *British Journal of Cancer*, **2003**, 89, 36-42	8.7	56
382	FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. *Clinical Colorectal Cancer*, **2014**, 13, 232-8	3.8	55
381	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. *British Journal of Cancer*, **2005**, 92, 1352-7	8.7	55
380	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *Journal of Clinical Oncology*, **2021**, JCO2101440	2.2	55
379	Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?. *Diseases of the Colon and Rectum*, **2011**, 54, 1251-9	3.1	54
378	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. *British Journal of Haematology*, **2003**, 120, 970-7	4.5	53
377	Ramucirumab: successfully targeting angiogenesis in gastric cancer. *Clinical Cancer Research*, **2014**, 20, 5875-81	12.9	52
376	MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 505-11	4	51
375	An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. *British Journal of Haematology*, **2001**, 115, 786-92	4.5	49
374	Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection. *Diseases of the Colon and Rectum*, **2009**, 52, 669-77	3.1	47
373	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. *Annals of Oncology*, **2016**, 27, 1557-65	10.3	47
372	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. *Cancer Discovery*, **2020**, 10, 657-663	24.4	46
371	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment **2019**, 7, 309		46

370	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. *European Journal of Cancer*, **2017**, 81, 17-25	7.5	45
369	Adjuvant therapy in colon cancer: current status and future directions. *Cancer Treatment Reviews*, **2002**, 28, 223-36	14.4	45
368	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. *Gut*, **2018**, 67, 1484-1492	19.2	45
367	PD-1 and PD-L1 blockade in gastrointestinal malignancies. *Cancer Treatment Reviews*, **2015**, 41, 893-903	14.4	44
366	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	44
365	Nivolumab □ ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.. *Journal of Clinical Oncology*, **2017**, 35, 4014-4014	2.2	44
364	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. *British Journal of Cancer*, **2016**, 115, 974-982	8.7	44
363	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. *Scientific Reports*, **2018**, 8, 1445	4.9	43
362	Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?. *World Journal of Gastroenterology*, **2014**, 20, 12391-406	5.6	43
361	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. *JAMA Oncology*, **2021**, 7, 895-902	13.4	43
360	Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. *Annals of Surgery*, **2014**, 259, 102-8	7.8	42
359	Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. *Journal of Clinical Oncology*, **2009**, 27, e3-4	2.2	42
358	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids **2019**, 7, 101		41
357	The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. *Annals of Oncology*, **2009**, 20, 885-91	10.3	41
356	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. *Journal of Clinical Oncology*, **2016**, 34, 4010-4010	2.2	41
355	A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. *Journal of Clinical Oncology*, **2004**, 22, 3023-31	2.2	40
354	Novel STAT 3 inhibitors for treating gastric cancer. *Expert Opinion on Investigational Drugs*, **2016**, 25, 1023-31	5.9	39
353	The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. *Annals of Oncology*, **2010**, 21, 1013-9	10.3	38

352	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. *Journal of Gastric Cancer*, **2017**, 17, 132-144	3.2	36
351	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. *Clinical Colorectal Cancer*, **2015**, 14, 115-22.e1-2	3.8	36
350	Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. *Journal of the American College of Surgeons*, **2013**, 217, 347-57.e1	4.4	35
349	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. *European Journal of Cancer*, **2013**, 49, 2116-25	7.5	34
348	Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. *European Journal of Cancer Care*, **2013**, 22, 714-25	2.4	34
347	The vital role of education and information in patients receiving capecitabine (Xeloda). *European Journal of Oncology Nursing*, **2004**, 8 Suppl 1, S41-53	2.8	34
346	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. *Lancet Haematology,the*, **2018**, 5, e190-e200	14.6	33
345	Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1607-13	4	33
344	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. *Clinical Cancer Research*, **2020**, 26, 183-192	12.9	33
343	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. *Oncotarget*, **2016**, 7, 12672-81	3.3	32
342	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. *Lancet Oncology, The*, **2018**, 19, e151-e160	21.7	31
341	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. *Critical Reviews in Oncology/Hematology*, **2019**, 143, 153-163	7	31
340	The genomic landscape of oesophagogastric junctional adenocarcinoma. *Journal of Pathology*, **2013** , 231, 301-10	9.4	31
339	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. *Clinical Chemistry*, **2018**, 64, 1626-1635	5.5	31
338	A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. *BMC Cancer*, **2014**, 14, 605	4.8	30
337	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.. *New England Journal of Medicine*, **2022**, 386, 449-462	59.2	30
336	Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. *JAMA Surgery*, **2014**, 149, 18-25	5.4	29
335	A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. *Journal of Clinical Oncology*, **2012**, 30, LBA4000-LBA4000	2.2	29

334	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. *British Journal of Radiology*, **2013**, 86, 20130281	3.4	28
333	Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. *British Journal of Cancer*, **2012**, 106, 1718-21	8.7	28
332	Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. *Annals of Oncology*, **2007**, 18, 730-7	10.3	28
331	Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. *Clinical Colorectal Cancer*, **2003**, 3, 19-33	3.8	28
330	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. *Journal of Clinical Oncology*, **2015**, 33, 2508-2508	2.2	28
329	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. *Journal of Clinical Oncology*, **2016**, 34, 6-6	2.2	28
328	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. *BMC Cancer*, **2015**, 15, 15	4.8	27
327	Pancreatic neuroendocrine tumors: a review. *Future Oncology*, **2015**, 11, 853-64	3.6	27
326	Management of resectable colorectal lung metastases. *Clinical and Experimental Metastasis*, **2016**, 33, 285-96	4.7	26
325	RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. *European Journal of Cancer*, **2014**, 50, 1430-6	7.5	26
324	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. *Annals of Oncology*, **2013**, 24, 3123-8	10.3	26
323	MRI-Diagnosed Tumour Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer. *Annals of Surgery*, **2020**,	7.8	26
322	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. *Nature Medicine*, **2021**, 27, 1362-1366	50.5	26
321	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. *Clinical Colorectal Cancer*, **2018**, 17, e69-e76	3.8	25
320	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. *European Journal of Cancer*, **2014**, 50, 1422-9	7.5	25
319	Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?. *New England Journal of Medicine*, **2002**, 346, 1085-7	59.2	25
318	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. *BMC Cancer*, **2015**, 15, 764	4.8	24
317	Patupilone in cancer treatment. *Expert Opinion on Investigational Drugs*, **2011**, 20, 107-17	5.9	24

316	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.. *Nature Cancer*, **2021**, 2, 1321-1337	15.4	24
315	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.. *Journal of Clinical Oncology*, **2021**, 39, LBA4001-LBA4001	2.2	24
314	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. *Oncologist*, **2017**, 22, 402-408	5.7	23
313	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. *Clinical Cancer Research*, **2019**, 25, 3830-3838	12.9	23
312	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. *BMC Cancer*, **2012**, 12, 326	4.8	23
311	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. *European Journal of Cancer*, **2011**, 47, 1146-51	7.5	23
310	Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. *British Journal of Cancer*, **2001**, 85, 1258-64	8.7	23
309	Chemotherapy in colorectal cancer: new options and new challenges. *British Medical Bulletin*, **2002**, 64, 159-80	5.4	23
308	Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. *Current Drug Targets*, **2017**, 18, 56-71	3	23
307	A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. *Clinical Colorectal Cancer*, **2014**, 13, 94-9	3.8	22
306	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. *ESMO Open*, **2020**, 5,	6	22
305	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. *Clinical Colorectal Cancer*, **2018**, 17, 280-284	3.8	22
304	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. *Clinical Cancer Research*, **2017**, 23, 6002-6011	12.9	21
303	Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?. *Clinical Colorectal Cancer*, **2016**, 15, e53-9	3.8	21
302	Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 5499-505	2.2	20
301	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. *Annals of Oncology*, **2012**, 23, 119-127	10.3	20
300	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. *European Journal of Cancer*, **2019**, 107, 115-123	7.5	20
299	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. *British Journal of Cancer*, **2018**, 119, 19-26	8.7	19

298	Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies. *Critical Reviews in Oncology/Hematology*, **2003**, 45, 151-76	7	19
297	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1 positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. *Journal of Clinical Oncology*, **2020**, 38, 4503-4503	2.2	19
296	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. *Clinical Cancer Research*, **2021**, 27, 3926-3935	12.9	19
295	Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. *Clinical Colorectal Cancer*, **2018**, 17, 223-230	3.8	19
294	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. *Annals of Oncology*, **2015**, 26, 1936-1941	10.3	18
293	Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. *Annals of the Royal College of Surgeons of England* , **2014**, 96, 543-6	1.4	18
292	Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. *Clinical Colorectal Cancer*, **2013**, 12, 15-22	3.8	18
291	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). *European Journal of Cancer*, **2013**, 49, 3507-16	7.5	18
290	Preoperative and postoperative chemotherapy for gastric cancer. *Surgical Oncology Clinics of North America*, **2012**, 21, 99-112	2.7	18
289	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. *European Journal of Cancer*, **2005**, 41, 1551-9	7.5	18
288	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. *Journal of Clinical Oncology*, **2018**, 36, 5-5	2.2	18
287	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. *European Journal of Cancer*, **2019**, 121, 40-47	7.5	17
286	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2014**, 32, 3518-3518	2.2	17
285	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. *Journal of Clinical Oncology*, **2017**, 35, 102-102	2.2	17
284	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. *Nature Cancer*, **2021**, 2, 1321-1337	15.4	17
283	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. *European Journal of Cancer*, **2019**, 108, 17-24	7.5	17
282	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. *Cancer Treatment Reviews*, **2020**, 86, 101998	14.4	17
281	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. *Annals of Oncology*, **2018**, 29, 230-236	10.3	16

280	The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: an exploratory study. *European Journal of Surgical Oncology*, **2015**, 41, 484-92	3.6	16
279	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. *British Journal of Cancer*, **2009**, 100, 1725-30	8.7	16
278	Gemcitabine and its combinations in the treatment of malignant lymphoma. *Clinical Lymphoma and Myeloma*, **2002**, 3, 97-104		16
277	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.. *Journal of Clinical Oncology*, **2016**, 34, 3056-3056	2.2	16
276	Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).. *Journal of Clinical Oncology*, **2018**, 36, 101-101	2.2	16
275	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). *European Journal of Cancer*, **2020**, 137, 45-56	7.5	16
274	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). *Heliyon*, **2018**, 4, e00804	3.6	16
273	Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. *Therapeutic Advances in Gastroenterology*, **2015**, 8, 373-83	4.7	15
272	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. *Gut*, **2018**, 67, 1780-1792	19.2	15
271	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. *JCO Precision Oncology*, **2019**, 3,	3.6	15
270	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. *European Journal of Cancer*, **2014**, 50, 3136-44	7.5	15
269	Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience. *Leukemia and Lymphoma*, **2007**, 48, 547-50	1.9	15
268	Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. *British Journal of Cancer*, **2003**, 88, 1510-5	8.7	15
267	Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. *Journal of Clinical Oncology*, **2011**, 29, 3523-3523	2.2	15
266	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. *International Journal of Cancer*, **2020**, 146, 94-102	7.5	15
265	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 814-824	4	14
264	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. *Oncologist*, **2016**, 21, 1502-1508	5.7	14
263	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. *JCO Precision Oncology*, **2018**, 2,	3.6	14

262	Gastric Cancer - From Aetiology to Management: Differences Between the East and the West. *Clinical Oncology*, **2019**, 31, 570-577	2.8	13
261	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. *International Journal of Radiation Oncology Biology Physics*, **2015**, 93, 303-12	4	13
260	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. *Oncologist*, **2018**, 23, 822-839	5.7	13
259	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. *Carcinogenesis*, **2016**, 37, 852-7	4.6	13
258	What studies are appropriate and necessary for staging gastric adenocarcinoma? Results of an international RAND/UCLA expert panel. *Gastric Cancer*, **2014**, 17, 377-82	7.6	13
257	The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis. *Clinical Nuclear Medicine*, **2015**, 40, e259-64	1.7	13
256	Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS213-TPS213	2.2	13
255	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. *Leukemia and Lymphoma*, **2017**, 58, 1805-1813	1.9	12
254	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. *Cancers*, **2019**, 11,	6.6	12
253	Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies. *Oncologist*, **2013**, 18, 833-42	5.7	12
252	Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom.. *Journal of Clinical Oncology*, **2011**, 29, 489-489	2.2	12
251	Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).. *Journal of Clinical Oncology*, **2014**, 32, 4016-4016	2.2	12
250	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated □-fetoprotein (AFP) from the randomized phase III REACH study.. *Journal of Clinical Oncology*, **2015**, 33, 232-232	2.2	12
249	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. *Journal of Clinical Oncology*, **2016**, 34, 154-154	2.2	12
248	CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS212-TPS212	2.2	12
247	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. *Journal of Clinical Oncology*, **2021**, 39, 3978-3992	2.2	12
246	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 289-298	8.9	12
245	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). *Clinical Colorectal Cancer*, **2019**, 18, 183-191.e3	3.8	11

244	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. *Clinical Colorectal Cancer*, **2019**, 18, 280-291.e5	3.8	11
243	What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. *Surgery*, **2013**, 154, 1100-9	3.6	11
242	A RAND/UCLA appropriateness study of the management of familial gastric cancer. *Annals of Surgical Oncology*, **2013**, 20, 533-41	3.1	11
241	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. *Annals of Oncology*, **2012**, 23, 942-7	10.3	11
240	6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. *European Journal of Cancer, Supplement*, **2009**, 7, 344-345	1.6	11
239	Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). *Hematology*, **2007**, 12, 149-53	2.2	11
238	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. *Journal of Clinical Oncology*, **2017**, 35, 4046-4046	2.2	11
237	CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. *Journal of Clinical*	2.2	11
236	CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.. *Journal of Clinical Oncology*, **2018**, 36, TPS193-TPS193	2.2	11
235	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. *Oncotarget*, **2017**, 8, 64999-65008	3.3	11
234	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. *Gut*, **2021**, 70, 1632-1641	19.2	11
233	Molecular target: pan-AKT in gastric cancer. *ESMO Open*, **2020**, 5, e000728	6	11
232	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. *Oncologist*, **2017**, 22, 728-736	5.7	10
231	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. *European Journal of Haematology*, **2015**, 94, 219-26	3.8	10
230	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. *BMC Cancer*, **2016**, 16, 112	4.8	10
229	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or	2.2	10
228	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. *Clinical Colorectal Cancer*, **2020**, 19, 32-38.e3	3.8	10
227	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. *Gastric Cancer*, **2020**, 23, 133-141	7.6	10

226	Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?. *Lancet, The*, **2017**, 390, 2418-2419	40	9
225	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. *Cancers*, **2019**, 11,	6.6	9
224	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. *Cancers*, **2020**, 12,	6.6	9
223	Bevacizumab-associated gastrointestinal perforation. *Lancet Oncology, The*, **2009**, 10, 534-6	21.7	9
222	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2015**, 126, 4263-4263	2.2	9
221	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. *Journal of Clinical Oncology*, **2014**, 32, TPS3114-TPS3114	2.2	9
220	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. *Journal of Clinical Oncology*, **2017**, 35, 9074-9074	2.2	9
219	POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.. *Journal of Clinical Oncology*, **2019**, 37, TPS3615-TPS3615	2.2	9
218	Genomic loss of heterozygosity and survival in the REAL3 trial. *Oncotarget*, **2018**, 9, 36654-36665	3.3	9
217	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. *Gut*, **2021**, 70, 1904-1913	19.2	9
216	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. *ESMO Open*, **2020**, 5,	6	9
215	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. *Cancer Treatment Reviews*, **2019**, 73, 31-40	14.4	9
214	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. *Gastric Cancer*, **2016**, 19, 1114-1124	7.6	8
213	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. *Annals of Hematology*, **2014**, 93, 827-34	3	8
212	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. *British Journal of Cancer*, **2011**, 104, 43-50	8.7	8
211	Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. *British Journal of Cancer*, **2010**, 102, 255-61	8.7	8
210	Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. *Clinical Colorectal Cancer*, **2003**, 3, 102-7	3.8	8
209	COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. *Journal of Clinical Oncology*, **2013**, 31, LBA4-LBA4	2.2	8

208	VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. *Journal of Clinical Oncology*, **2014**, 32, 2533-2533	2.2	8
207	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. *Journal of Clinical Oncology*, **2020**, 38, 430-430	2.2	8
206	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. *Cancers*, **2020**, 12,	6.6	8
205	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. *World Journal of Gastrointestinal Oncology*, **2018**, 10, 159-171	3.4	8
204	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. *Gastric Cancer*, **2021**, 1	7.6	8
203	Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. *Drugs*, **2016**, 76, 13-26	12.1	7
202	Neoadjuvant therapy before surgical treatment. *European Journal of Cancer, Supplement*, **2013**, 11, 45-59	1.6	7
201	FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease. *Clinical Cancer Research*, **2014**, 20, 4511-9	12.9	7
200	Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. *Pancreas*, **2013**, 42, 511-5	2.6	7
199	Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm?. *Seminars in Radiation Oncology*, **2011**, 21, 196-202	5.5	7
198	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) + ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) **2019**,		7
197	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. *Blood*, **2016**, 128, 624-624	2.2	7
196	EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.. *Journal of Clinical Oncology*, **2011**, 29, 3513-3513	2.2	7
195	REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.. *Journal of Clinical Oncology*, **2011**, 29, 4131-4131	2.2	7
194	Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2018**, 36, 658-658	2.2	7
193	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. *ESMO Open*, **2020**, 5,	6	7
192	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. *Leukemia and Lymphoma*, **2018**, 59, 1586-1595	1.9	7
191	Neoadjuvant rectal score: run with the hare and hunt with the hounds. *Annals of Oncology*, **2018**, 29, 2261-2262	10.3	7

190	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). *BMJ Open*, **2020**, 10, e034527	3	6
189	Immunotherapy for oesophagogastric cancer. *Expert Opinion on Biological Therapy*, **2016**, 16, 1197-207	5.4	6
188	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. *Frontiers in Oncology*, **2019**, 9, 618	5.3	6
187	Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. *Investigational New Drugs*, **2013**, 31, 1339-44	4.3	6
186	MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS530-TPS530	2.2	6
185	Capecitabine in gastric cancer. *Drugs of Today*, **2008**, 44, 629-40	2.5	6
184	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. *European Radiology*, **2020**, 30, 6702-6708	8	6
183	Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. *American Journal of Roentgenology*, **2021**, 216, 669-676	5.4	6
182	Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. *Translational Gastroenterology and Hepatology*, **2016**, 1, 46	5.2	6
181	LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. *Annals of Oncology*, **2021**, 32, S1332	10.3	6
180	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 933-946	18.8	6
179	Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. *Hematology/Oncology Clinics of North America*, **2017**, 31, 529-544	3.1	5
178	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. *Current Problems in Cancer*, **2019**, 43, 487-494	2.3	5
177	The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. *British Journal of Haematology*, **2018**, 180, 52-59	4.5	5
176	Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. *Clinical Colorectal Cancer*, **2017**, 16, e181-e189	3.8	5
175	The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. *European Journal of Cancer*, **2015**, 51, 2732-9	7.5	5
174	Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. *Immunotherapy*, **2014**, 6, 1177-86	3.8	5
173	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. *Journal of Clinical Oncology*, **2014**, 32, 3575-3575	2.2	5

172	Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. *Seminars in Radiation Oncology*, **2016**, 26, 176-85	5.5	5
171	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. *Therapeutic Advances in Medical Oncology*, **2016**, 8, 104-12	5.4	5
170	Ramucirumab and its use in the treatment of hepatocellular carcinoma. *Future Oncology*, **2019**, 15, 979-988	3.8	5
169	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. *Clinical Colorectal Cancer*, **2019**, 18, 64-71.e1	3.8	5
168	The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. *Supportive Care in Cancer*, **2021**, 29, 1443-1453	3.9	5
167	Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. *Journal of Clinical Oncology*, **2021**, 39, 102-102	2.2	5
166	O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. *Annals of Oncology*, **2020**, 31, 236	10.3	4
165	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. *Clinical Cancer Research*, **2020**, 26, 3546-3556	12.9	4
164	Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP). *Annals of Oncology*, **2016**, 27, vi182	10.3	4
163	Trastuzumab for gastric cancer treatment. *Lancet, The*, **2010**, 376, 1736; author reply 1736-7	40	4
162	Primary follicular lymphoma of the GI tract: an increasingly recognized entity. *Journal of Clinical Oncology*, **2012**, 30, e370-2	2.2	4
161	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. *Journal of Clinical*	2.2	4
160	CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS4132-TPS4132	2.2	4
159	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. *Journal of Clinical Oncology*, **2017**, 35, 3-3	2.2	4
158	TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer. A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2020**, 38, TPS4120-TPS4120	2.2	4
157	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 280-291	7.1	4
156	Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. *Canadian Journal of Cardiology*, **2017**, 33, 1336.e9-1336.e12	3.8	3
155	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. *Expert Review of Anticancer Therapy*, **2020**, 20, 251-270	3.5	3

154	LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy. *British Journal of Haematology*, **2020**, 189, e248-e251	4.5	3
153	Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. *Expert Review of Anticancer Therapy*, **2018**, 18, 327-338	3.5	3
152	Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial. *Annals of Oncology*, **2016**, 27, vi220	10.3	3
151	Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. *BMC Hematology*, **2018**, 18, 19	2.5	3
150	Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma. *Cancer Treatment Reviews*, **2017**, 59, 132-137	14.4	3
149	Investigational therapies targeting the ErbB family in oesophagogastric cancer. *Expert Opinion on Investigational Drugs*, **2014**, 23, 1349-63	5.9	3
148	An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. *Investigational New Drugs*, **2013**, 31, 1228-35	4.3	3
147	Capecitabine in advanced gastric cancer. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 2851-61	4	3
146	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials.. *Expert Opinion on Investigational Drugs*, **2022**,	5.9	3
145	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. *Blood*, **2018**, 132, 2892-2892	2.2	3
144	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2016**, 128, 480-480	2.2	3
143	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.. *Journal of Clinical*	2.2	3
142	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. *Journal of Clinical Oncology*, **2015**, 33, 4029-4029	2.2	3
141	PLATFORM: Planning treatment of oesophago-gastric (OG) cancer: A randomised maintenance therapy trial.. *Journal of Clinical Oncology*, **2016**, 34, TPS187-TPS187	2.2	3
140	CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS4131-TPS4131	2.2	3
139	Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.. *Journal of Clinical Oncology*, **2018**, 36, 3059-3059	2.2	3
138	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS4139-TPS4139	2.2	3
137	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. *Annals of Hematology*, **2020**, 99, 105-112	3	3

136	F-choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma. *British Journal of Haematology*, **2021**, 193, 1026	4.5	3
135	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. *Journal of Clinical Oncology*, **2021**, 39, TPS3620-TPS3620	2.2	3
134	MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF). *Journal of Thoracic Oncology*, **2019**, 14, S307	8.9	3
133	Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.. *Journal of Clinical Oncology*, **2021**, 39, 201-201	2.2	3
132	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. *Expert Review of Hematology*, **2016**, 9, 123-35	2.8	2
131	Rare case of cerebral MALToma presenting with stroke-like symptoms and seizures. *BMJ Case Reports*, **2013**, 2013,	0.9	2
130	A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT).. *Journal of Clinical Oncology*, **2010**, 28, TPS191-TPS191	2.2	2
129	HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. *Journal of Clinical Oncology*, **2013**, 31, 420-420	2.2	2
128	Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 4067-4067	2.2	2
127	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. *Journal of Clinical Oncology*, **2014**, 32, TPS4147-TPS4147	2.2	2
126	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. *Journal of Clinical Oncology*, **2014**, 32, 489-489	2.2	2
125	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. *Journal of Clinical Oncology*, **2016**, 34, TPS178-TPS178	2.2	2
124	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. *Journal of Clinical Oncology*, **2017**, 35, 7537-7537	2.2	2
123	Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).. *Journal of Clinical Oncology*, **2017**, 35, TPS7579-TPS7579	2.2	2
122	Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. *Journal of Clinical Oncology*, **2018**, 36, 401-401	2.2	2
121	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).. *Journal of Clinical Oncology*, **2019**, 37, 4022-4022	2.2	2
120	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. *World Journal of Gastrointestinal Oncology*, **2017**, 9, 333-340	3.4	2
119	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 548-548	2.2	2

118	Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study		2
117	A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).. *Journal of Clinical Oncology*, **2012**, 30, TPS4146-TPS4146	2.2	2
116	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. *Nature Ecology and Evolution*, **2021**, 5, 1024-1032	12.3	2
115	Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. *Journal of Clinical Oncology*, **2021**, 39, 4015-4015	2.2	2
114	Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. *Clinical Radiology*, **2021**, 76, 789-800	2.9	2
113	Targeting the Stroma in the Management of Pancreatic Cancer. *Frontiers in Oncology*, **2021**, 11, 691185	5.3	2
112	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. *Expert Review of Gastroenterology and Hepatology*, **2021**, 15, 1159-1167	4.2	2
111	443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers phase IIA dose finding. *Annals of Oncology*, **2021**, 32, S555-S556	10.3	2
110	386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). *Annals of Oncology*, **2021**, 32, S532	10.3	2
109	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
108	HER2 targeted therapy in colorectal cancer: New horizons.. *Cancer Treatment Reviews*, **2022**, 105, 102363	14.4	2
107	Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. *BMC Gastroenterology*, **2020**, 20, 133	3	1
106	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. *European Journal of Cancer*, **2020**, 135, 103-112	7.5	1
105	Focal splenic lesions in indolent B-NHL: association with high grade transformation and safe percutaneous biopsy. *British Journal of Haematology*, **2020**, 189, e157-e160	4.5	1
104	Emerging precision therapies for gastric cancer. *Expert Review of Precision Medicine and Drug Development*, **2020**, 5, 299-311	1.6	1
103	Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response. *Colorectal Disease*, **2018**, 20 Suppl 1, 76-81	2.1	1
102	EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R-GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES. *Hematological Oncology*, **2019**, 37, 425-426	1.3	1
101	Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. *European Journal of Cancer*, **2019**, 122, 12-21	7.5	1

100	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Review of Anticancer Therapy*, **2017**, 17, 951-964	3.5	1
99	Nonsurgical management of esophageal adenocarcinoma. *Clinical Colorectal Cancer*, **2011**, 10, 165-70	3.8	1
98	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. *Blood*, **2014**, 124, 1719-1719	2.2	1
97	A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. *Journal of Clinical Oncology*, **2012**, 30, LBA4000-LBA4000	2.2	1
96	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. *Journal of Clinical Oncology*, **2013**, 31, e14616-e14616	2.2	1
95	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.. *Journal of Clinical Oncology*, **2015**, 33, 4077-4077	2.2	1
94	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. *Journal of Clinical Oncology*, **2015**, 33, 581-581	2.2	1
93	Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience.. *Journal of Clinical Oncology*, **2016**, 34, 644-644	2.2	1
92	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. *Journal of Clinical Oncology*, **2017**, 35, 2004-2004	2.2	1
91	Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD.. *Journal of Clinical Oncology*, **2017**, 35, 4047-4047	2.2	1
90	A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.. *Journal of Clinical Oncology*, **2017**, 35, TPS4138-TPS4138	2.2	1
89	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. *Journal of Clinical Oncology*, **2018**, 36, e16207-e16207	2.2	1
88	Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032.. *Journal of Clinical Oncology*, **2018**, 36, 51-51	2.2	1
87	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. *Journal of Clinical Oncology*, **2018**, 36, 90-90	2.2	1
86	Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).. *Journal of Clinical Oncology*, **2019**, 37, 128-128	2.2	1
85	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. *Journal of Clinical Oncology*, **2020**, 38, 3089-3089	2.2	1
84	Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.. *Journal of Clinical Oncology*, **2020**, 38, 282-282	2.2	1
83	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. *Nature Communications*, **2021**, 12, 6738	17.4	1

82	Complications and seeding risk after percutaneous liver biopsy in an oncological setting.. *Journal of Clinical Oncology*, **2018**, 36, 246-246	2.2	1
81	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. *Journal of Clinical Oncology*, **2018**, 36, 4044-4044	2.2	1
80	Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer		1
79	Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data		1
78	iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.. *Journal of Clinical Oncology*, **2017**, 35, TPS221-TPS221	2.2	1
77	Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. *Journal of Clinical Oncology*, **2017**, 35, 709-709	2.2	1
76	Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. *Journal of Comparative Effectiveness Research*, **2020**, 9, 103-114	2.1	1
75	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. *Frontiers in Oncology*, **2020**, 10, 1634	5.3	1
74	Are treatment response assessment maps (TRAMs) and F-choline positron emission tomography the future of central nervous system lymphoma imaging?. *British Journal of Haematology*, **2021**, 195, e116-e119	4.5	1
73	A very rare complication of subdural haematoma: fibrin-associated diffuse large B-cell lymphoma. *British Journal of Haematology*, **2021**, 192, 947	4.5	1
72	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. *Advances in Therapy*, **2021**, 38, 707-720	4.1	1
71	Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. *Quantitative Imaging in Medicine and Surgery*, **2021**, 11, 3549-3561	3.6	1
70	Colon and rectum308-326		1
69	Chemotherapy for Advanced Pancreatic Cancer **2010**, 913-949		1
68	Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.. *Expert Opinion on Drug Safety*, **2022**, 1-9	4.1	0
67	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. *Journal of Clinical Oncology*, **2022**, 40, TPS224-TPS224	2.2	0
66	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. *Journal of Clinical Oncology*, **2020**, 38, 712-712	2.2	0
65	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. *Expert Opinion on Investigational Drugs*, **2021**, 1-19	5.9	0

64	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 1429-1441	4	0
63	Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer. *Lancet Oncology, The*, **2021**, 22, 739-741	21.7	0
62	Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. *Journal of Clinical Oncology*, **2021**, 39, e16074-e16074	2.2	0
61	Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. *Anticancer Research*, **2018**, 38, 5943-5949	2.3	0
60	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. *Pharmacogenomics*, **2021**, 22, 703-726	2.6	0
59	A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. *Blood Advances*, **2021**, 5, 4073-4082	7.8	0
58	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. *Leukemia and Lymphoma*, **2021**, 1-13	1.9	0
57	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases.. *Cancer Imaging*, **2021**, 21, 67	5.6	0
56	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. *Trials*, **2020**, 21, 431	2.8	
55	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Review of Anticancer Therapy*, **2020**, 20, 305-324	3.5	
54	Chemotherapy for Advanced Pancreatic Cancer **2018**, 875-921		
53	The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL. *Blood*, **2020**, 136, 31-32	2.2	
52	Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.. *Journal of Clinical Oncology*, **2020**, 38, 212-212	2.2	
51	SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.. *Journal of Clinical Oncology*, **2020**, 38, TPS471-TPS471	2.2	
50	A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. *Journal of Clinical Oncology*, **2020**, 38, TPS459-TPS459	2.2	
49	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Review of Anticancer Therapy*, **2021**, 1-13	3.5	
48	Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. *Leukemia and Lymphoma*, **2021**, 1-11	1.9	
47	[18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool. *F1000Research*,10, 1137	3.6	

46	Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?. *Bone Marrow Transplantation*, **2021**,	4.4
45	What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).. *Journal of Clinical Oncology*, **2018**, 36, e16023-e16023	2.2
44	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. *Journal of Clinical Oncology*, **2018**, 36, e15127-e15127	2.2
43	Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience. *Blood*, **2018**, 132, 4240-4240	2.2
42	Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).. *Journal of Clinical Oncology*, **2019**, 37, 102-102	2.2
41	CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.. *Journal of Clinical Oncology*, **2019**, 37, 535-535	2.2
40	A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial. *Blood*, **2019**, 134, 2879-2879	2.2
39	Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location.. *Journal of Clinical Oncology*, **2020**, 38, 304-304	2.2
38	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. *Journal of Clinical Oncology*, **2020**, 38, e16537-e16537	2.2
37	Exclusion of patients with prior cancers from clinical trials: Is this justified?. *Journal of Clinical Oncology*, **2014**, 32, 6544-6544	2.2
36	FCGR2IIa and FCGR3IIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. *Journal of Clinical Oncology*, **2014**, 32, 3573-3573	2.2
35	LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).. *Journal of Clinical*	2.2
34	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.. *Journal of Clinical Oncology*, **2014**, 32, TPS3653-TPS3653	2.2
33	Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma. *Blood*, **2014**, 124, 3971-3971	2.2
32	Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [18f]FDG-PET Prior to Allogeneic Transplant. *Blood*, **2014**, 124, 1249-1249	2.2
31	Toxicity and efficacy of salvage paclitaxel chemotherapy in Royal Marsden (RM) oesophagogastric adenocarcinoma (OGA) patients (pts).. *Journal of Clinical Oncology*, **2015**, 33, 188-188	2.2
30	A prospective patient (pt) survey on clinical trials.. *Journal of Clinical Oncology*, **2015**, 33, 707-707	2.2
29	Trends in resected oesophageal and gastric adenocarcinoma (OGA) outcomes: Royal Marsden (RM) experience 2001-2010.. *Journal of Clinical Oncology*, **2015**, 33, 169-169	2.2

28	Formulating a surveillance strategy following surgery for oesophagogastric cancer.. *Journal of Clinical Oncology*, **2015**, 33, 153-153	2.2
27	FOrMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors.. *Journal of Clinical Oncology*, **2015**, 33, TPS227-TPS227	2.2
26	Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.. *Journal of Clinical Oncology*, **2015**, 33, 4028-4028	2.2
25	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. *Journal of Clinical Oncology*, **2015**, 33, 4108-4108	2.2
24	Anus327-332	
23	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. *Blood*, **2015**, 126, 1499-1499	2.2
22	A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.. *Journal of Clinical Oncology*, **2016**, 34, 580-580	2.2
21	The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.. *Journal of Clinical Oncology*, **2016**, 34, TPS10143-TPS10143	2.2
20	Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases: Implications for targeted treatment.. *Journal of Clinical Oncology*, **2016**, 34, e15027-e15027	2.2
19	Chemotherapy for Advanced Pancreatic Cancer **2017**, 1-48	
18	Colon and Rectum308-326	
17	Anus327-332	
16	Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 613-613	2.2
15	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. *Journal of Clinical Oncology*, **2012**, 30, e14088-e14088	2.2
14	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 31-31	2.2
13	Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.. *Journal of Clinical Oncology*, **2013**, 31, 78-78	2.2
12	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. *Journal of Clinical Oncology*, **2014**, 32, 447-447	2.2
11	Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.. *Journal of Clinical Oncology*, **2014**, 32, 91-91	2.2

10	The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience.. *Journal of Clinical Oncology*, **2014**, 32, 622-622	2.2
9	Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.. *Journal of Clinical Oncology*, **2014**, 32, 316-316	2.2
8	Early interval and serial positron emission tomography-computed tomography (PET-CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma. *British Journal of Haematology*, **2020**, 190, e357-e362	4.5
7	Chemotherapy for Advanced Pancreatic Cancer **2016**, 1-48	
6	Colorectal cancer trial endpoints: time for dynamic thinking?. *Lancet Oncology, The*, **2016**, 17, 1345-1347	21.7
5	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. *Current Colorectal Cancer Reports*, **2018**, 14, 138-151	1
4	Approach to Immunotherapy in Oesophageal Cancer **2022**, 1	
3	Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.. *Current Oncology*, **2022**, 29, 2174-2184	2.8
2	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. *Cancer Research*, **2022**, 82, PR012-PR012	10.1
1	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. *Cancer Research*, **2022**, 82, A002-A002	10.1